Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
News|Articles|March 8, 2012
FDA Issues Guidance Agenda for 2012
Author(s)Angie Drakulich
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are approximately 50 such guidances planned.
Advertisement
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such
In biopharmaceutics and biosimilarity:
- Food-Effect Bioavailability and Fed Bioequivalence Studies-Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Submitted in New Drug Applications General Consideration
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product (draft already issued)
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product (draft already issued)
- Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (draft already issued)
In combination products:
- Development of Drugs in Combination
In CGMPs and compliance:
- Control of Highly Potent Compounds
- Expiration Dating of Unit-Dose Repackaged Drugs: Compliance Policy Guide
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
In labeling, packaging, and supply chain:
- Naming, Labeling, and Packaging Practices to Reduce Medication Errors
- Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
- Drug Names and Dosage Forms
- Organ-Specific Warnings: Internal Analgesic, Antipyretic and Antirheumatic Drug Products for Over-the-Counter Human Use-Labeling of Products That Contain Acetaminophen
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
In regulatory filings (electronic):
- Providing Regulatory Submissions in Electronic Format – General Considerations
- Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
- Providing Regulatory Submissions in Electronic Format – Study Data
- Providing Regulatory Submissions in Electronic Format – Standardized Study Data
Advertisement
Related to this article
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Advertisement
Advertisement